This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at danial.baker@wsu.edu.
Comparative agents:
Alemtuzumab for cancer (Campath)
Indication:
Treatment of patients with relapsing forms of multiple sclerosis (MS). Generally reserved for patients who have had an inadequate response to 2 or more drugs indicated for the treatment of MS.
Mechanism of action:
CD52-directed cytolytic monoclonal antibody that binds to CD52, a cell surface antigen present on T and B lymphocytes, and on natural killer cells, monocytes, and macrophages resulting in an antibody-dependent cellular cytolysis and complement-mediated lysis. Once-daily oral 2-drug combination for the treatment of chronic hepatitis C genotype 1 without peginterferon plus ribavirin Current FDA-Related Drug Information 
